Frame J D, Verbrugge G P, Gill R G, Pinneo L
Trans R Soc Trop Med Hyg. 1984;78(3):319-24. doi: 10.1016/0035-9203(84)90107-x.
Lassa fever convalescent plasma (LFCP) has been administered to 27 patients in hospitals at Jos and Vom, Nigeria. Among serologically or virologically confirmed cases of Lassa fever (LF) given plasma on or before the 10th day, all eight survived, as did two of three possible LF cases. Of eight patients given LFCP after the 10th day, five died, as did all three possible LF cases. LFCP was also administered to five patients subsequently shown not to have LF, and to a suspected case contact; all survived without complications of therapy. There were 15 cases of LF during this time who did not receive plasma; 11 survived. Most cases of LF who received plasma and survived showed a rapid response to therapy, in contrast with the gradual recovery in those who did not receive LFCP.
在尼日利亚乔斯和沃姆的医院里，已对27名患者使用了拉沙热康复期血浆（LFCP）。在第10天或之前接受血浆治疗的血清学或病毒学确诊的拉沙热（LF）病例中，8名患者全部存活，3例可能的LF病例中有2例存活。在第10天后接受LFCP治疗的8名患者中，5例死亡，3例可能的LF病例也全部死亡。LFCP还用于5名后来被证明没有患LF的患者以及1名疑似病例的接触者；所有这些人均存活，且未出现治疗并发症。在此期间，有15例LF患者未接受血浆治疗；其中11例存活。大多数接受血浆治疗并存活的LF病例对治疗反应迅速，这与未接受LFCP治疗的患者逐渐康复形成对比。
